- Corporate Officers - K
- Karsen Perry A
Insider Trading History of Karsen Perry A
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Karsen Perry A since 2013.
The trader's CIK number is 1260573.
At the time of the last reporting, Karsen Perry A was the Director of Intellia Therapeutics, Inc.. (stock ticker symbol NTLA).
Also see all insider trading activities at Intellia Therapeutics, Inc..
Note that in the past
KARSEN PERRY A also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Intellia Therapeutics, Inc. (NTLA) by Karsen Perry A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | NTLA | 0 | $0 | 88,764 | $4,750,027 | 88,764 | $1,644,619 |
Yearly summary of insider trading at Celgene Corp /de/ (CELG) by Karsen Perry A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | CELG | 0 | $0 | 94,342 | $10,960,603 | 108,734 | $3,118,824 |
| 2014 | CELG | 0 | $0 | 92,854 | $9,783,346 | 90,191 | $3,062,680 |
| 2013 | CELG | 0 | $0 | 93,008 | $13,625,672 | 135,785 | $4,555,934 |
Yearly summary of insider trading at Oncomed Pharmaceuticals Inc (OMED) by Karsen Perry A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | OMED | 10,000 | $34,590 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Jounce Therapeutics, Inc. (JNCE) by Karsen Perry A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | JNCE | 5,000 | $80,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by Karsen Perry A:
1. Intellia Therapeutics, Inc. (NTLA)
2. Celgene Corp /de/ (CELG)
3. Oncomed Pharmaceuticals Inc (OMED)
4. Jounce Therapeutics, Inc. (JNCE)
Table 1. Insider trading of Intellia Therapeutics, Inc. (NTLA) by Karsen Perry A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-12-17 | NTLA | Sale | 88,764 | 53.51 | 4,750,027 |
| 2020-12-17 | NTLA | Option Ex | 88,764 | 18.53 | 1,644,619 |
Table 2. Insider trading of Celgene Corp /de/ (CELG) by Karsen Perry A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-12-17 | CELG | Option Ex | 7,500 | .00 | 0 |
| 2015-05-13 | CELG | Option Ex | 30,470 | 45.52 | 1,386,963 |
| 2013-05-13 | CELG | Sale | 47,173 | 115.00 | 5,424,895 |
| 2015-04-30 | CELG | Option Ex | 11,200 | .00 | 0 |
| 2015-03-01 | CELG | Option Ex | 8,334 | .00 | 0 |
| 2015-02-11 | CELG | Option Ex | 27,896 | 37.20 | 1,037,675 |
| 2015-02-11 | CELG | Sale | 27,896 | 120.11 | 3,350,728 |
| 2014-12-30 | CELG | Option Ex | 23,334 | 29.75 | 694,186 |
| 2014-12-30 | CELG | Sale | 19,273 | 113.37 | 2,184,980 |
| 2014-11-12 | CELG | Option Ex | 32,074 | 33.06 | 1,060,462 |
| 2014-11-12 | CELG | Sale | 39,420 | 107.23 | 4,227,006 |
| 2014-08-04 | CELG | Sale | 39,104 | 87.55 | 3,423,437 |
| 2014-08-04 | CELG | Option Ex | 46,450 | 28.16 | 1,308,032 |
| 2014-05-01 | CELG | Sale | 11,922 | 146.78 | 1,749,911 |
| 2014-05-01 | CELG | Option Ex | 11,667 | 59.50 | 694,186 |
| 2014-03-03 | CELG | Sale | 2,408 | 159.05 | 382,992 |
| 2013-12-27 | CELG | Option Ex | 7,777 | .00 | 0 |
| 2013-11-01 | CELG | Option Ex | 10,000 | .00 | 0 |
| 2013-08-02 | CELG | Sale | 93,008 | 146.50 | 13,625,672 |
| 2013-08-02 | CELG | Option Ex | 118,008 | 38.61 | 4,555,934 |
Table 3. Insider trading of Oncomed Pharmaceuticals Inc (OMED) by Karsen Perry A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-06-05 | OMED | Buy | 10,000 | 3.46 | 34,590 |
Table 4. Insider trading of Jounce Therapeutics, Inc. (JNCE) by Karsen Perry A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-02-01 | JNCE | Buy | 5,000 | 16.00 | 80,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Karsen Perry A
(Director of Intellia Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.